Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Receivables (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Change in Receivables for 7 consecutive years, with -$425000.0 as the latest value for Q3 2025.

  • For Q3 2025, Change in Receivables changed N/A year-over-year to -$425000.0; the TTM value through Sep 2025 reached $100000.0, changed N/A, while the annual FY2024 figure was $556000.0, 679.17% up from the prior year.
  • Change in Receivables hit -$425000.0 in Q3 2025 for Cyclerion Therapeutics, down from -$56000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $556000.0 in Q4 2024 and bottomed at -$425000.0 in Q3 2025.
  • Average Change in Receivables over 5 years is $7692.3, with a median of -$56000.0 recorded in 2025.
  • On a YoY basis, Change in Receivables climbed as much as 200.0% in 2022 and fell as far as 200.0% in 2022.
  • Cyclerion Therapeutics' Change in Receivables stood at -$58000.0 in 2021, then plummeted by 125.86% to -$131000.0 in 2022, then grew by 26.72% to -$96000.0 in 2023, then surged by 679.17% to $556000.0 in 2024, then plummeted by 176.44% to -$425000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$425000.0, -$56000.0, and $25000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.